换肤

科美诊断

i问董秘

A04038

主营介绍

  • 主营业务：

    从事临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售

  • 产品类型：

    LiCA系列、CC系列

  • 产品名称：

    LiCA500 、 LiCA800 、 LiCASmart 、 LiCA4000 、 CC1500

  • 经营范围：

    研究、开发化学发光免疫分析检测技术；提供技术咨询、技术服务、技术转让；分析检测技术培训；批发医疗器械II、Ⅲ类（国家法律、法规及限制性产业规定需要专项审批的，未获审批前不得经营）；销售自产产品；佣金代理（拍卖除外）；货物进出口（不涉及国营贸易管理商品；涉及配额、许可证管理商品的；按国家有关规定办理申请）；医疗器械租赁；生产医疗器械II、III类（医疗器械生产许可证有效期至2023年10月07日）。（依法须经批准的项目，经相关部门批准后依批准的内容开展经营活动。）

主营构成分析

报告期
报告期
{"2020-06-30":{"YYSR":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","11805.77"],["CC\u7cfb\u5217\u4ea7\u54c1","3086.39"],["\u5176\u4ed6","246.14"]],"3":[["\u534e\u4e1c\u5730\u533a","5835.60"],["\u897f\u5357\u5730\u533a","2514.90"],["\u534e\u5317\u5730\u533a","1799.00"],["\u534e\u4e2d\u5730\u533a","1689.40"],["\u534e\u5357\u5730\u533a","1380.10"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1918.9]]},"YYCB":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","3110.67"],["CC\u7cfb\u5217\u4ea7\u54c1","1311.77"],["\u5176\u4ed6","293.73"]],"3":[["\u534e\u4e1c\u5730\u533a",""],["\u897f\u5357\u5730\u533a",""],["\u534e\u5317\u5730\u533a",""],["\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","83.43"],["CC\u7cfb\u5217\u4ea7\u54c1","17.03"],["\u5176\u4ed6","-0.46"]],"3":[["\u534e\u4e1c\u5730\u533a",""],["\u897f\u5357\u5730\u533a",""],["\u534e\u5317\u5730\u533a",""],["\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}},"2019-12-31":{"YYSR":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","29922.99"],["CC\u7cfb\u5217\u4ea7\u54c1","15368.21"],["\u5176\u4ed6","175.45"]],"3":[["\u534e\u4e1c\u5730\u533a","18114.63"],["\u897f\u5357\u5730\u533a","6756.81"],["\u534e\u4e2d\u5730\u533a","5494.39"],["\u534e\u5317\u5730\u533a","5473.96"],["\u534e\u5357\u5730\u533a","3791.19"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",5835.67]]},"YYCB":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","6786.78"],["CC\u7cfb\u5217\u4ea7\u54c1","4484.02"],["\u5176\u4ed6","104.06"]],"3":[["\u534e\u4e1c\u5730\u533a",""],["\u897f\u5357\u5730\u533a",""],["\u534e\u4e2d\u5730\u533a",""],["\u534e\u5317\u5730\u533a",""],["\u534e\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","67.86"],["CC\u7cfb\u5217\u4ea7\u54c1","31.93"],["\u5176\u4ed6","0.21"]],"3":[["\u534e\u4e1c\u5730\u533a",""],["\u897f\u5357\u5730\u533a",""],["\u534e\u4e2d\u5730\u533a",""],["\u534e\u5317\u5730\u533a",""],["\u534e\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}},"2018-12-31":{"YYSR":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","20314.46"],["CC\u7cfb\u5217\u4ea7\u54c1","16092.38"],["\u5176\u4ed6","199.01"]],"3":[["\u534e\u4e1c\u5730\u533a","15151.41"],["\u897f\u5357\u5730\u533a","5017.82"],["\u534e\u5317\u5730\u533a","4545.06"],["\u534e\u4e2d\u5730\u533a","4385.97"],["\u534e\u5357\u5730\u533a","2867.88"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",4637.72]]},"YYCB":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","4832.37"],["CC\u7cfb\u5217\u4ea7\u54c1","4796.19"],["\u5176\u4ed6","151.34"]],"3":[["\u534e\u4e1c\u5730\u533a",""],["\u897f\u5357\u5730\u533a",""],["\u534e\u5317\u5730\u533a",""],["\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]},"LRBL":{"2":[["LiCA\u7cfb\u5217\u4ea7\u54c1","57.71"],["CC\u7cfb\u5217\u4ea7\u54c1","42.11"],["\u5176\u4ed6","0.18"]],"3":[["\u534e\u4e1c\u5730\u533a",""],["\u897f\u5357\u5730\u533a",""],["\u534e\u5317\u5730\u533a",""],["\u534e\u4e2d\u5730\u533a",""],["\u534e\u5357\u5730\u533a",""],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0]]}}}
{"YYSR":{"chartWrap2":[{"name":"LiCA\u7cfb\u5217\u4ea7\u54c1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[11805.77,29922.99,20314.46],"columnData":[77.99,65.81,55.5],"unit":["1.18\u4ebf","2.99\u4ebf","2.03\u4ebf"]},{"name":"CC\u7cfb\u5217\u4ea7\u54c1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[3086.39,15368.21,16092.38],"columnData":[20.39,33.8,43.96],"unit":["3086.39\u4e07","1.54\u4ebf","1.61\u4ebf"]},{"name":"\u5176\u4ed6","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[246.14,175.45,199.01],"columnData":[1.63,0.39,0.54],"unit":["246.14\u4e07","175.45\u4e07","199.01\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[5835.6,18114.63,15151.41],"columnData":[38.55,39.84,41.39],"unit":["5835.60\u4e07","1.81\u4ebf","1.52\u4ebf"]},{"name":"\u897f\u5357\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[2514.9,6756.81,5017.82],"columnData":[16.61,14.86,13.71],"unit":["2514.90\u4e07","6756.81\u4e07","5017.82\u4e07"]},{"name":"\u534e\u5317\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[1799,5473.96,4545.06],"columnData":[11.88,12.04,12.42],"unit":["1799.00\u4e07","5473.96\u4e07","4545.06\u4e07"]},{"name":"\u534e\u4e2d\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[1689.4,5494.39,4385.97],"columnData":[11.16,12.08,11.98],"unit":["1689.40\u4e07","5494.39\u4e07","4385.97\u4e07"]},{"name":"\u534e\u5357\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[1380.1,3791.19,2867.88],"columnData":[9.12,8.34,7.83],"unit":["1380.10\u4e07","3791.19\u4e07","2867.88\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[1918.9,5835.67,4637.72],"columnData":[12.67,12.83,12.67],"unit":["1918.90\u4e07","5835.67\u4e07","4637.72\u4e07"]}]},"YYCB":{"chartWrap2":[{"name":"LiCA\u7cfb\u5217\u4ea7\u54c1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[3110.67,6786.78,4832.37],"columnData":[65.96,59.66,49.41],"unit":["3110.67\u4e07","6786.78\u4e07","4832.37\u4e07"]},{"name":"CC\u7cfb\u5217\u4ea7\u54c1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[1311.77,4484.02,4796.19],"columnData":[27.81,39.42,49.04],"unit":["1311.77\u4e07","4484.02\u4e07","4796.19\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[293.73,104.06,151.34],"columnData":[6.23,0.91,1.55],"unit":["293.73\u4e07","104.06\u4e07","151.34\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u897f\u5357\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5317\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u4e2d\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]},"LRBL":{"chartWrap2":[{"name":"LiCA\u7cfb\u5217\u4ea7\u54c1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[83.43,67.86,57.71],"columnData":[83.43,67.86,57.71],"unit":["83.43\u4e07","67.86\u4e07","57.71\u4e07"]},{"name":"CC\u7cfb\u5217\u4ea7\u54c1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[17.03,31.93,42.11],"columnData":[17.03,31.93,42.11],"unit":["17.03\u4e07","31.93\u4e07","42.11\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[-0.46,0.21,0.18],"columnData":[-0.46,0.21,0.18],"unit":["-4600","2100.00","1800.00"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u897f\u5357\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5317\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u4e2d\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u534e\u5357\u5730\u533a","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2020-06-30","2019-12-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 LiCA系列产品 1.18亿 77.99% 3110.67万 65.96% 83.43% 73.65%
CC系列产品 3086.39万 20.39% 1311.77万 27.81% 17.03% 57.50%
其他 246.14万 1.63% 293.73万 6.23% -0.46% -19.33%
按地区 华东地区 5835.60万 38.55% - - - -
西南地区 2514.90万 16.61% - - - -
华北地区 1799.00万 11.88% - - - -
华中地区 1689.40万 11.16% - - - -
华南地区 1380.10万 9.12% - - - -
西北地区 1272.10万 8.40% - - - -
东北地区 646.80万 4.27% - - - -

董事会经营评述

　　一、盈利能力分析
　　报告期内，公司盈利能力分析具体情况如下：
　　（一）影响公司收入、成本、费用和利润的主要因素及具有核心意义的财务或非
　　财务指标
　　1、影响收入、成本、费用和利润的主要因素
　　（1）影响收入的主要因素
　　公司是一家主要从事临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售的高新技术企业，公司产品为基于光激化学发光法的LiCA系列诊断试剂和基于酶促化学发光法的CC系列诊断试剂及仪器，公司的销售收入也主要来自于两个部分。影响公司收入的主要因素是产品的市场规模和需求、产品竞争力。
　　1）市场规模和需求
　　公司化学发光体外诊断试剂产品主要应用于传染病（如乙肝、丙... 查看全部▼

　　一、盈利能力分析
　　报告期内，公司盈利能力分析具体情况如下：
　　（一）影响公司收入、成本、费用和利润的主要因素及具有核心意义的财务或非
　　财务指标
　　1、影响收入、成本、费用和利润的主要因素
　　（1）影响收入的主要因素
　　公司是一家主要从事临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售的高新技术企业，公司产品为基于光激化学发光法的LiCA系列诊断试剂和基于酶促化学发光法的CC系列诊断试剂及仪器，公司的销售收入也主要来自于两个部分。影响公司收入的主要因素是产品的市场规模和需求、产品竞争力。
　　1）市场规模和需求
　　公司化学发光体外诊断试剂产品主要应用于传染病（如乙肝、丙肝、艾滋病、梅毒、甲肝、戊肝等）标志物、肿瘤标志物、甲状腺激素、生殖内分泌激素、心肌标志物及炎症等的检测。随着人均可支配收入及人均医疗保健支出逐年提高，在居民健康理念提升和人口老龄化趋势等因素的推动下，体外诊断需求持续扩张，未来增长空间仍较大。同时，分级诊疗制度推进带动基层医疗机构诊断需求提升、进口替代的政策支持等因素亦未公司营业收入的增长奠定了广阔的市场基础。
　　2）产品竞争力
　　公司产品具有技术应用优势及质量优势。公司产品的核心技术包括光激化学发光及应用技术、酶促化学发光及应用技术和标志物检测技术，基于上述核心技术，公司产品具有技术应用优势和质量优势，产品具有竞争力。
　　（2）影响成本的主要因素
　　公司产品成本由直接材料、直接人工、制造费用和仪器折旧构成，其中直接材料和仪器折旧占比较大。公司采购的主要物料为试剂原辅料、仪器及配件和耗材及包材，报告期内，发行人采购的生物活性原料存在一定程度的波动主要系采购周期、市场行情等因素影响，单次采购量较大。报告期内，公司采购仪器及配件和耗材及包材的价格总体保持稳定。
　　（3）影响费用的主要因素
　　公司期间费用包括销售费用、管理费用、研发费用和财务费用。剔除计入管理费用的股份支付因素影响，报告期内，公司的期间费用总额分别为12,279.49万元、16,218.21万元和19,473.05万元，随公司经营规模的扩大而增长，主要系销售费用及研发费用增长。
　　（4）影响利润的主要因素
　　影响公司利润的主要因素是主营业务毛利及期间费用，即营业收入的实现和营业成本、期间费用的控制。
　　2、影响公司业绩变动的主要财务或非财务指标
　　（1）主营业务收入和毛利率是影响公司业绩变动的主要财务指标
　　报告期内公司营业收入整体复合增长率为19.46%，其中LiCA系列产品作为公司近年来的战略重点增长迅速，年均复合增长率超过45%。光激化学发光技术作为一种“免分离”的均相免疫分析方法，具有纳米、免洗和光激发的特点，基于光激化学发光技术的LiCA系列产品在检测灵敏度、精密度和特异性等方面均有良好表现。近年来公司在维持CC系列产品既有业务的基础上，着力开拓LiCA系列产品市场，LiCA系列产品销售收入持续快速增长。
　　主营业务毛利率可用来判断公司产品的竞争力和获利能力。报告期内，公司综合毛利率分别为72.18%、73.28%和74.98%，总体保持平稳，毛利率保持稳定且处于较高水平。公司产品具有较强的市场竞争力和获利能力。
　　（2）在研产品储备和销售渠道拓展是影响公司业绩变动的主要非财务指标
　　公司目前的研发重点是基于光激化学发光法补充完善产品线，重点补充生殖健康领域等产品线，同时开展生殖内分泌激素、类风湿以及新型艾滋病检测等产品的研发。公司目前的项目储备充足，截至2020年4月30日，公司已进入临床阶段和注册评审阶段的在研项目共有21项。丰富的在研产品储备一方面可以确保现有产品线的完整性，技术前沿性，满足不断提升的市场需求；另一方面，通过不断创新和新品研发，可以拓宽公司产品布局、降低经营风险，保证公司业绩持续增长。公司主要采用经销模式销售产品，报告期内，公司经销商客户逐渐增加，销售渠道不断拓展。
　　（二）营业收入
　　1、营业收入整体情况
　　报告期内，公司营业收入保持增长态势，2018年及2019年主营业务收入分别同比增长14.89%及24.21%，公司主营业务收入持续增长主要源于LiCA系列化学发光产品的销售。
　　报告期内，公司收入全部为主营业务收入，不存在明显季节性波动。
　　2、主营业务收入的产品及技术平台构成分析
　　从技术方法类型上，公司主要产品为基于光激化学发光（LiCA系列产品）和酶促化学发光（CC系列产品）两个免疫技术平台的检测试剂，报告期内，LiCA系列产品收入占比不断升高，其从43.63%上升至65.81%。
　　从病种类型上，传染病系列产品是公司主打产品线，传染病系列产品也是公司历史收入增长的主要驱动产品。报告期内，传染病系列产品营业收入合计占比约90%。公司其他化学发光产品系列（肿瘤系列、甲状腺系列、生殖内分泌激素系列、肝纤系列和糖尿病系列）目前规模较小。
　　3、主营业务收入的地域构成分析
　　报告期内，公司销售收入全部来源于国内，华东地区、华北地区和西南地区销售占比较大。 收起▲

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。